Simultaneous Determination of Paroxetine, Risperidone and 9-Hydroxyrisperidone in Human Plasma by High-Performance Liquid Chromatography with Coulometric Detection

A method for the simultaneous determination of paroxetine, risperidone and its main metabolite 9-hydroxyrisperidone in human plasma has been developed. The procedure involved a multistep solid-phase liquid extraction with an internal standard. The drugs were separated on a cyano column followed by coulometric detection. This method described here has sufficient sensitivity to quantitate paroxetine accurately in the range 5–500 ng/ml with a lower limit of detection of 1 ng/ml and risperidone and its main metabolite 9-hydroxyrisperidone in the range 2–100 ng/ml with a lower limit of detection of 1 ng/ml when 1 ml of plasma was used for the analysis. The precision, accuracy and specificity have been proven, and show that the method is reliable for clinical studies and routine drug monitoring.

[1]  Jae-Gook Shin,et al.  Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[2]  C. Eap,et al.  Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. , 1998, Journal of chromatographic science.

[3]  O. Olesen,et al.  Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[4]  D. Hoffman,et al.  Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. , 1997, Therapeutic drug monitoring.

[5]  D. Sorisio,et al.  Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[6]  M. Brett,et al.  A simple and robust HPLC method for the determination of paroxetine in human plasma. , 1995, Journal of pharmaceutical and biomedical analysis.

[7]  R. Gupta,et al.  Column liquid chromatographic determination of bupivacaine in human serum using solid-phase extraction. , 1994, Journal of chromatography. B, Biomedical applications.

[8]  A. Szegedi,et al.  Automated Determination of Paroxetine and Its Main Metabolite by Column Switching and On‐Line High‐Performance Liquid Chromatography , 1994, Therapeutic drug monitoring.

[9]  R. Gupta Column liquid chromatographic determination of paroxetine in human serum using solid-phase extraction. , 1994, Journal of chromatography. B, Biomedical applications.

[10]  J. Levron,et al.  Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. , 1993, Journal of chromatography.

[11]  S. Marder,et al.  Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. , 1993, Journal of pharmaceutical sciences.

[12]  J. Heykants,et al.  Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. , 1992, Journal of chromatography.

[13]  Johnson Am Paroxetine: a pharmacological review. , 1992 .

[14]  A. M. Johnson Paroxetine: A Pharmacological Review , 1992, International clinical psychopharmacology.

[15]  J. Feighner,et al.  An overview of paroxetine. , 1992, The Journal of clinical psychiatry.

[16]  M. Hariharan,et al.  An Improved Sensitive Assay for Simultaneous Determination of Plasma Haloperidol and Reduced Haloperidol Levels by Liquid Chromatography Using a Coulometric Detector , 1989, Therapeutic drug monitoring.

[17]  J. C. Stoof,et al.  Biochemical profile of risperidone, a new antipsychotic. , 1988, The Journal of pharmacology and experimental therapeutics.

[18]  S. Heylen,et al.  Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration. , 1988, Acta psychiatrica Belgica.

[19]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[20]  M. Brett,et al.  Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. , 1987, Journal of chromatography.

[21]  L. Wetterberg,et al.  Potent depletion of 5HT from monkey whole blood by a new 5HT uptake inhibitor, paroxetine (FG 7051). , 1978, European journal of pharmacology.